JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Therapeutic Effect of Selenium Nanoparticles, Sorafenib, and Selenium-Sorafenib Nanocomplex in the Lungs and Kidneys of Mice with TAA-Induced HCC

  • 0Institute of Cell Biophysics of the Russian Academy of Sciences, Federal Research Center "Pushchino Scientific Center for Biological Research of the Russian Academy of Sciences", 142290 Pushchino, Russia.
Biomolecules +

|

September 27, 2025

|

September 27, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Hepatocellular carcinoma (HCC) can spread to the lungs and kidneys. This study investigated gene expression changes in these organs and the effectiveness of selenium nanocomplexes and sorafenib in mitigating HCC

Area Of Science

  • Oncology
  • Translational Medicine
  • Nanotechnology

Background

  • Hepatocellular carcinoma (HCC) is a primary liver cancer with high mortality due to late diagnosis and metastasis.
  • Understanding pathological changes in metastatic sites like the lungs and kidneys is crucial for effective treatment.
  • The liver and kidneys are key organs affected by toxicity, necessitating investigation into their roles in HCC progression.

Purpose Of The Study

  • To analyze mRNA expression patterns in the lungs and kidneys of mice with thioacetamide-induced HCC.
  • To evaluate the therapeutic potential of selenium nanocomplexes and sorafenib in mitigating HCC-related pathological changes.
  • To establish the distribution hierarchy of selenium in organs after treatment for optimizing drug dosages.

Main Methods

  • Induction of Hepatocellular Carcinoma (HCC) in mice using thioacetamide.
  • Analysis of mRNA expression profiles related to inflammation, ER stress, cell death, and signaling pathways in lung and kidney tissues.
  • Administration of selenium nanocomplexes and sorafenib to assess their impact on pathological processes and organ toxicity.

Main Results

  • Detailed mRNA expression patterns were identified in the lungs and kidneys of mice with HCC.
  • Selenium nanocomplexes and sorafenib demonstrated potential in mitigating pathological consequences of HCC metastasis.
  • A clear distribution hierarchy of selenium was established in the liver, kidneys, and lungs post-treatment.

Conclusions

  • This study provides novel insights into the molecular mechanisms of HCC metastasis to the lungs and kidneys.
  • Selenium nanocomplexes and sorafenib show promise as therapeutic agents for advanced HCC.
  • Findings support the development of optimized treatment protocols and drug dosages for improved therapeutic outcomes and reduced toxicity.

Keywords: